InvestorsHub Logo
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

Re: vanmaarsum post# 3705

Sunday, 06/03/2007 7:29:27 PM

Sunday, June 03, 2007 7:29:27 PM

Post# of 19309
Re: Novozymes

Thanks for posting this informative write-up. A few comments:

>the company has also developed a number of animal-free recombinant versions of the widely used serum protein albumin for large-scale biomanufacturing.<

Increasing competition from recombinant albumin is one of the reasons GTC has effectively dropped its own albumin program. The overall supply is just too large for anyone to make a lot of money on albumin.

>The contamination risk from pathogens such as viruses or prions when using animal-derived ingredients, and the damage the BSE crisis caused some manufacturers, is pushing some companies towards animal-free alternatives in a bid to eliminate the threat.<

This is true, but the main fallout from this policy is IMO a preference for recombinant proteins vs plasma-derived proteins. Hence, I consider GTC a net beneficiary of this movement despite the fact that its proteins are derived from animals.

>Although firms opting for the animal-free [cell culture] ingredients will be paying for the added safety and productivity the products offer, the company was unable to disclose any specific pricing details.<

Price will be very important, of course. The most compelling long-term argument for GTC’s platform is an economic one. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.